Melissa Haendel, PhD, professor in the Department of Biochemistry and Molecular Genetics at the University of Colorado School of Medicine, and her team of data scientists have been working at a lightning-fast pace for two years, unlocking some of the mysteries of long COVID. Not only have they been instrumental in the development of the largest national, publicly available HIPAA-limited dataset in U.S. history – the National COVID Cohort Collaborative (N3C) – but their research using the data is making headlines and getting the attention of the White House.

Wendy Meyer | July 20, 2022

Our mission at the CCTSI is to help build research teams of the future, speed the development of new treatments and improve human health. Pediatric oncologist and researcher Dr. Mike Verneris exemplifies this mission through his work with the Consortium for Pediatric Cellular Immunotherapy (CPCI). It’s a mouthful, but the gist of it is a group of five children’s hospitals (and their research institutes like the CCTSI) are working together to share deep and specialized knowledge about developing cellular therapy to treat cancers and other pediatric illnesses.

Wendy Meyer | June 07, 2022

The massive volume of messages we all have received about COVID-19 led the World Health Organization to coin the term “infodemic”: too much information, including false or misleading messages, in digital and physical environments during a disease outbreak. Though academics will be studying the toll of this misinformation for many years to come, we know it has been massive.

Wendy Meyer | June 07, 2022

Ten years ago, people with cystic fibrosis (CF) celebrated when the FDA approved ivacaftor, the first drug designed to target the defective protein that causes the disease. CF is an inherited disorder that inflicts severe damage to the lungs, digestive system and other organs in the body. Since then, several additional drugs that use a similar mechanism have been approved by the FDA for CF.

Wendy Meyer | June 07, 2022

Dear CCTSI research community,

CTSA Applications

Last month we submitted a suite of six Clinical Translational Science Award (CTSA) grant applications to NCATS/NIH for the competing renewal of the CCTSI. The grants included a UM1, K12, Pre-doc T32, Post-doc T32 and two RC2 Specialized Innovative Program applications. The scientific and administrative leadership of the CCTSI and I have been preparing for these submissions for more than a year. In addition, we brought experts from CTSAs across the country to review our grant plans and drafts; it is a rigorous and iterative process. Many of us have been writing and submitting grants to the NIH for decades, but this effort (submitting six NIH grants simultaneously) stands out as monumental!

Ronald J. Sokol. MD | June 07, 2022

Researchers are working to better prepare for the next pandemic.

Wendy Meyer | May 16, 2022

In 2020, the Adult and Child Center for Outcomes Research and Delivery Science (ACCORDS) education program at the School of Medicine at the University of Colorado Anschutz Medical Campus, was awarded a three-year conference grant from the Agency for Healthcare Research and Quality (AHRQ). After successfully offering two virtual conferences in 2020 and 2021, ACCORDS, and co-sponsor Colorado Clinical and Translational Sciences Institute (CCTSI), are proud to offer the third annual Colorado Pragmatic Research in Health Conference (COPRH Con) on May 23-25, 2022, as a hybrid event. Anschutz Medical Campus employees and CCTSI members from affiliated institutions can attend this year’s conference for free.

Katie Klossner | May 09, 2022

The Colorado Clinical and Translational Sciences Institute (CCTSI) is pleased to announce that Matthew DeCamp, MD, PhD, will assume the role as the new leader of its research ethics program. Marilyn Coors, PhD, who served in this role since 2010, recently retired from the University of Colorado Anschutz Medical Campus. Dr. DeCamp is associate professor in the Center for Bioethics and Humanities and Division of General Internal Medicine in the School of Medicine.

Wendy Meyer | March 14, 2022

When Marilyn Coors, PhD, took a job as an assistant professor in the Center for Bioethics and Humanities at the University of Colorado Anschutz Medical Campus, she had a vision. She wanted the center to become an integral part of the operation of science, research and teaching on the state’s top medical campus. Today, more than 21 years later, it is clear her vision has been realized.

Wendy Meyer | March 14, 2022

A recent study published in the Proceedings of the National Academy of Sciences by a team of researchers at the University of Colorado Anschutz Medical Campus significantly advances the understanding of a key aspect of the immune system during COVID-19: the interferon response.

Chelsea Donohoe | March 02, 2022

Children’s Hospital Colorado (Children’s Colorado), the University of Colorado School of Medicine (CU School of Medicine) and the University of Colorado Anschutz Medical Campus (CU Anschutz Campus) are announcing that Ronald J. Sokol, MD, will become the inaugural Chief Scientific Officer, Child Health, effective May 1, 2022. As an experienced research leader and expert in pediatric liver disease and transplantation, Dr. Sokol will help formalize a joint research enterprise across the CU Anschutz Campus to promote discovery and increase understanding of childhood diseases, while also advancing clinical care to improve health across the entire lifespan. 

Staff | February 08, 2022

The National Institutes of Health (NIH) has invested nearly $470 million to build a national study population of diverse research volunteers and support large-scale studies on the long-term effects of COVID-19. The Colorado Clinical and Translational Sciences Institute (CCTSI) is playing a major role in the initiative called REsearching COVID to Enhance Recovery or RECOVER.

Wendy Meyer | February 07, 2022

You never know when inspiration will strike. For biostatistician Conner Jackson, MS, his inspiration was a pet tortoise named Pietro. Pietro’s owner insisted the tortoise could predict the weather through his behavior. The topic came up in a Zoom meeting one day and Jackson was captivated. “I expected everyone to say, ‘we should look into that!'"

Wendy Meyer | December 14, 2021

The CCTSI Pilot Grant Program is probably the best-known of our CCTSI offerings. Yet, word on the street is that securing a pilot grant can be challenging. These one-year awards are certainly competitive—and we believe they are essential to catalyzing and accelerating translational research in Colorado. Our goal is to enable junior investigators, technology-experienced scientists and community-collaborative researchers to jumpstart their ideas, generate data, develop technologies for larger grants, clinical trials and ultimately improve patient care and public health.

Debra Szuster, MS | December 14, 2021

In 1991, Karen Morgenthaler started a new position working for Dr. Chip Ridgway in the endocrinology lab at the University of Colorado School of Medicine. After 30 years of service for the university, most of which took place in the lab at the Colorado Clinical and Translational Sciences Institute (CCTSI), Karen will retire at the end of 2021.

Wendy Meyer | December 13, 2021

1. CCTSI stands for the Colorado Clinical and Translational Sciences Institute.

2. We help build the research teams of the future, speed the development of new treatments and improve human health

Wendy Meyer | September 14, 2021

The pandemic has changed how we work. As a result, you may find yourself ferrying a laptop around more often. With this comes an increased risk it will be stolen, lost or damaged during transit. So, what are some things you can do to protect the sensitive data on your laptop? 

Matthew Latus | September 14, 2021

In March of 2020, the pandemic drove Coloradans to enter lockdown mode. This was no different for researchers on the CU Anschutz Medical Campus. The result was that research operations were completely shuttered unless they were related to COVID-19 or essential to patient care.

Wendy Meyer | September 14, 2021

Phil Zeitler, MD, PhD, has been treating youth with type 2 diabetes for more than 20 years. He and a team of researchers published a paper today on the TODAY2 study in the New England Journal of Medicine on the long-term complications of type 2 diabetes. (TODAY stands for Treatment Options for type 2 Diabetes in Adolescents and Youth. The first phase of the study took place from 2004 - 2011; phase two from 2011 - 2020. Both studies involved more than 550 participants from across the country.)

Wendy Meyer | July 28, 2021

March 5, 2020 marked the anniversary of the first confirmed case of COVID-19 in Colorado. Just a few days later, on March 10, Governor Polis declared a state of emergency and soon thereafter most of us were working from home and living in full pandemic mode.

Wendy Meyer | June 24, 2021

As Colorado surpasses a 47 percent rate of its population being fully immunized (with 12 counties surpassing 70 percent), researchers continue to expand the study of the vaccines on children as young as five years old. The Pediatric Clinical and Translational Research Center (CTRC) and its nursing staff are playing a major role.

Wendy Meyer | June 24, 2021

The CCTSI is pleased to announce two new leadership roles: Jose R. Castillo-Mancilla, MD and Christopher D. Baker, MD will each serve as Associate Medical Director of the Clinical and Translational Research Centers of the CCTSI. Dr. Baker will oversee the pediatric CTRC at Children’s Hospital Colorado under the leadership of Medical Director Dr. Phil Zeitler. Dr. Castillo-Mancia will oversee the adult CTRC at UCHealth under the leadership of Medical Director Dr. Tom Campbell.

Wendy Meyer | June 24, 2021

In vaccine clinical trials, the Pfizer and Moderna COVID-19 vaccines were shown to be about 95%  effective in preventing COVID-19. Now a study from the Centers for Disease Control and Prevention uses real-world data to show that indeed, those who are 65 years and older who are fully vaccinated are 94% percent less likely to be hospitalized for COVID-19 than those who have not been vaccinated. Researchers enrolled hospitalized patients from 20 hospitals across the nation—including UCHealth University of Colorado Hospital.

Wendy Meyer | May 11, 2021

The nation has been coping with the pandemic for more than a year, and in this time, researchers have learned a great deal about how to treat COVID-19. Yet they have also been faced with what they still must learn, including how to reach the individuals who have been most dramatically impacted by the disease and who could benefit the most from new treatments. 

Wendy Meyer | March 30, 2021

Associate Professor of Medicine Lilia Cervantes, MD is a homegrown success story, a physician researcher and a changemaker. Growing up in Denver and receiving her undergraduate degree from CU Boulder, she went on to earn her medical degree and complete her internal medicine residency at the CU School of Medicine. For the past 12 years, she has worked as an internal medicine hospitalist at Denver Health, the safety-net hospital in Denver. Dr. Cervantes’ research describes the worse outcomes of undocumented immigrants with kidney failure who rely only on emergency dialysis. As a result of Dr. Cervantes’ research and advocacy, in 2019 Colorado Medicaid opted to include the diagnosis of kidney failure as a qualifying condition under Emergency Medicaid, expanding access to standard dialysis. Recently, she published a qualitative study on the experiences of Latinx individuals hospitalized for COVID-19.

Wendy Meyer | March 30, 2021

One year ago, CCTSI researchers and staff were told to continue our programs of research from home to keep ourselves, our colleagues, families and communities safe from COVID-19. Books and files were collected, labs were closed, clinical trials were put on hold, teaching and program management were moved online. Makeshift offices were created in closets, bedrooms, garages and on kitchen counters. I found myself at home with my husband and two teenagers. I continued my research where I could and connected with colleagues over Zoom while supporting my family through the COVID-19 lockdown.

Heather M. Gilmartin | March 30, 2021

They say necessity is the mother of invention. In terms of healthcare, one of the most remarkable inventions begat by the pandemic is something called the National COVID Cohort Collaborative (N3C). The vision of the scientists and researchers behind the N3C is to turn massive amounts of already available data into new knowledge urgently needed to study COVID-19 and identify potential treatments.

The speed at which the N3C has moved is astonishing: In just a little over six months, the initiative was launched, made available to biomedical researchers and has already produced its first publication.

Wendy Meyer | February 17, 2021

Vaccine hesitancy is something we hear a lot about these days related to a potential coronavirus vaccine. Yet vaccine hesitancy has been a public health issue in the U.S. for many years. In 2019, a measles outbreak associated with vaccine refusal in religious communities infected 1,282 Americans—the most cases since 1992. And from 2006-2011, the rate of kindergarteners opting out of school-required vaccinations tripled.

Wendy Meyer | October 27, 2020

Here at the Anschutz Medical Campus, we are in the business of answering important research questions in order to improve human health. One of the ways our physicians and scientists do this is through research studies that involve human participants who volunteer to make the studies possible.

Guest Contributor | December 17, 2019

For some researchers who spend their days tucked away in a lab, the impact of their work may at times seem removed from the lives of real people. Not so for Dr. Kevin Messacar, pediatric infectious disease specialist. In his mind, he has considered himself a physician first, researcher second since he came to Children’s Hospital Colorado in 2009.

Guest Contributor | October 01, 2019

The University of Colorado Anschutz Medical Campus is part of a team of researchers that has received a grant of $3.6 million for the SPROUT-CTSA Collaborative Telehealth Research Network

Guest Contributor | April 15, 2019

Researchers from the University of  Colorado Anschutz Medical Campus, in collaboration with several other institutions, have discovered a genetic defect linked to Biliary atresia (BA), the most common pediatric cause of end-stage liver disease, and the leading indication for liver transplantation in children.

Staff | February 21, 2019

The battle between good and evil is a theme usually reserved for blockbuster movies or literature. However, biomedical researcher Donald Leung, MD, PhD, is engaged in his own epic battle, pitting good bacteria against bad in order to treat atopic dermatitis or eczema – the world’s most common skin disease.

Staff | May 29, 2018